Giancarlo Pruneri Selected Research

Cyclin D3

1/2005	Cyclin D3 immunoreactivity is an independent predictor of survival in laryngeal squamous cell carcinoma.
10/2004	Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index.
9/2003	Cyclin D3 immunoreactivity in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification and is associated with nuclear p27 accumulation.
8/2003	Immunoreactivity for cyclin D3 is frequently detectable in high-grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Giancarlo Pruneri Research Topics

Disease

99	Neoplasms (Cancer) 11/2022 - 10/2000
77	Breast Neoplasms (Breast Cancer) 11/2022 - 10/2002
10	Neoplasm Metastasis (Metastasis) 06/2020 - 02/2005
7	Triple Negative Breast Neoplasms 01/2022 - 07/2012
7	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2020 - 03/2003
7	Lymphoma (Lymphomas) 03/2014 - 01/2003
5	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 05/2009
4	Multiple Myeloma 11/2020 - 09/2002
4	Carcinoma (Carcinomatosis) 01/2018 - 04/2013
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2015 - 06/2002
3	Disease Progression 11/2022 - 01/2019
3	Melanoma (Melanoma, Malignant) 11/2022 - 07/2012
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021 - 08/2003
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 11/2017
3	Hodgkin Disease (Hodgkin's Disease) 01/2019 - 01/2009
3	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/2015 - 10/2004
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 09/2010 - 03/2006
3	B-Cell Lymphoma (Lymphoma, B Cell) 06/2009 - 08/2003
3	Squamous Cell Carcinoma of Head and Neck 02/2005 - 03/2004
2	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2019
2	Hyperglycemia 01/2021 - 01/2021
2	Thyroid Neoplasms (Thyroid Cancer) 01/2020 - 01/2019
2	Stomach Neoplasms (Stomach Cancer) 01/2019 - 01/2018
2	Adenocarcinoma of Lung 01/2019 - 03/2014
2	Glioblastoma (Glioblastoma Multiforme) 01/2018 - 07/2012
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2017 - 10/2002
2	Carcinogenesis 12/2016 - 10/2002
2	Breast Ductal Carcinoma 10/2015 - 04/2012
2	Insulin Resistance 11/2014 - 07/2012
2	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 03/2014 - 10/2003
2	Leukemia 09/2010 - 11/2008
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 02/2006 - 12/2005

Drug/Important Bio-Agent (IBA)

28	Biomarkers (Surrogate Marker)IBA 07/2022 - 09/2002
16	Estrogen ReceptorsIBA 06/2020 - 10/2004
12	Phenobarbital (Luminal)FDA Link 01/2019 - 07/2012
10	human ERBB2 proteinIBA 07/2022 - 02/2013
9	Hormones (Hormone)IBA 01/2021 - 10/2004
8	DNA (Deoxyribonucleic Acid)IBA 03/2021 - 03/2004
8	Progesterone Receptors (Progesterone Receptor)IBA 02/2015 - 10/2004
7	Immune Checkpoint InhibitorsIBA 12/2021 - 10/2016
7	Rituximab (Mabthera)FDA Link 12/2015 - 10/2003
7	Monoclonal AntibodiesIBA 12/2015 - 06/2002
6	Histones (Histone)IBA 01/2021 - 03/2016
6	Proteins (Proteins, Gene)FDA Link 01/2019 - 08/2002
6	Biological ProductsIBA 01/2016 - 04/2005
6	Pharmaceutical PreparationsIBA 10/2015 - 11/2008
5	Trastuzumab (Herceptin)FDA Link 07/2022 - 05/2003
5	ParaffinIBA 11/2021 - 07/2012
5	Formaldehyde (Formol)FDA Link 11/2021 - 07/2012
5	Messenger RNA (mRNA)IBA 01/2021 - 10/2002
4	RNA (Ribonucleic Acid)IBA 01/2022 - 06/2004
4	EnzymesIBA 01/2021 - 09/2007
4	Cisplatin (Platino)FDA LinkGeneric 01/2019 - 09/2007
4	Metformin (Glucophage)FDA LinkGeneric 01/2019 - 07/2012
4	ErbB Receptors (EGF Receptor)IBA 12/2017 - 08/2011
4	Cyclin D3IBA 01/2005 - 08/2003
3	PlatinumIBA 10/2022 - 12/2018
3	Antineoplastic Agents (Antineoplastics)IBA 01/2022 - 11/2014
3	Aromatase InhibitorsIBA 01/2021 - 01/2017
3	MethyltransferasesIBA 11/2019 - 07/2012
3	Tamoxifen FDA LinkGeneric 01/2017 - 06/2013
3	Tyrosine Kinase InhibitorsIBA 10/2015 - 08/2011
3	Estrogens (Estrogen)FDA Link 08/2014 - 10/2005
3	Cyclin D1IBA 10/2008 - 01/2005
3	N 30IBA 12/2007 - 01/2003
2	Mechanistic Target of Rapamycin Complex 1IBA 11/2022 - 01/2021
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2021 - 01/2019
2	exemestane (Aromasin)FDA Link 01/2021 - 01/2016
2	Everolimus FDA Link 01/2021 - 01/2019
2	Fatty Acid Synthases (Fatty Acid Synthase)IBA 01/2021 - 01/2019
2	AntibodiesIBA 01/2019 - 09/2002
2	Small Interfering RNA (siRNA)IBA 01/2019 - 12/2016
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2019 - 01/2018
2	Hypoglycemic Agents (Hypoglycemics)IBA 01/2019 - 11/2014
2	Eosine Yellowish-(YS) (Eosin)IBA 09/2017 - 01/2016
2	Hematoxylin (Haematoxylon)IBA 09/2017 - 01/2016
2	Insulin-Like Growth Factor I (IGF-1)IBA 01/2016 - 11/2014
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2015 - 10/2006
2	Progesterone FDA LinkGeneric 02/2015 - 04/2013
2	Alkylating AgentsIBA 08/2014 - 07/2012
2	NucleophosminIBA 09/2010 - 03/2006
2	Cladribine FDA LinkGeneric 08/2010 - 05/2010
2	SteroidsIBA 07/2009 - 10/2004
2	Protein Isoforms (Isoforms)IBA 05/2008 - 07/2005
2	AntigensIBA 04/2005 - 12/2003
2	EndoglinIBA 02/2005 - 12/2004
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2004 - 01/2003
2	Cyclin EIBA 01/2003 - 01/2003
1	Drug CombinationsIBA 11/2022

Therapy/Procedure

41	Therapeutics 11/2022 - 01/2003
18	Drug Therapy (Chemotherapy) 11/2022 - 01/2003
6	Immunotherapy 01/2022 - 04/2005
5	Neoadjuvant Therapy 12/2021 - 05/2009
5	Adjuvant Chemotherapy 04/2021 - 07/2009
4	Mammaplasty (Breast Reconstruction) 10/2021 - 01/2012
4	Radiotherapy 10/2021 - 06/2009
3	Mastectomy (Mammectomy) 04/2017 - 03/2003
2	Aftercare (After-Treatment) 01/2022 - 01/2019
2	Transplantation 01/2021 - 11/2008
2	Lymph Node Excision (Lymph Node Dissection) 03/2006 - 02/2005